Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment.
Identifieur interne : 002F34 ( Ncbi/Curation ); précédent : 002F33; suivant : 002F35Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment.
Auteurs : H J Zheng [République populaire de Chine] ; Z H Tao ; W F Cheng ; S H Wang ; S H Cheng ; Y M Ye ; L F Luo ; X R Chen ; G B Gan ; W F PiessensSource :
- The American journal of tropical medicine and hygiene [ 0002-9637 ] ; 1991.
Descripteurs français
- KwdFr :
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Anticorps antihelminthe (sang), Antigènes d'helminthe (immunologie), Antigènes d'helminthe (sang), Diéthylcarbamazine (administration et posologie), Diéthylcarbamazine (usage thérapeutique), Facteur de nécrose tumorale alpha (analyse), Femelle, Filariose lymphatique (immunologie), Filariose lymphatique (traitement médicamenteux), Humains, Hypersensibilité immédiate, Interleukines (sang), Ivermectine (administration et posologie), Ivermectine (usage thérapeutique), Microfilaria (immunologie), Mâle, Wuchereria bancrofti (immunologie).
- MESH :
- administration et posologie : Diéthylcarbamazine, Ivermectine.
- analyse : Facteur de nécrose tumorale alpha.
- immunologie : Antigènes d'helminthe, Filariose lymphatique, Microfilaria, Wuchereria bancrofti.
- sang : Anticorps antihelminthe, Antigènes d'helminthe, Interleukines.
- traitement médicamenteux : Filariose lymphatique.
- usage thérapeutique : Diéthylcarbamazine, Ivermectine.
- Adolescent, Adulte, Adulte d'âge moyen, Animaux, Femelle, Humains, Hypersensibilité immédiate, Mâle.
English descriptors
- KwdEn :
- Adolescent, Adult, Animals, Antibodies, Helminth (blood), Antigens, Helminth (blood), Antigens, Helminth (immunology), Diethylcarbamazine (administration & dosage), Diethylcarbamazine (therapeutic use), Elephantiasis, Filarial (drug therapy), Elephantiasis, Filarial (immunology), Female, Humans, Hypersensitivity, Immediate, Interleukins (blood), Ivermectin (administration & dosage), Ivermectin (therapeutic use), Male, Microfilariae (immunology), Middle Aged, Tumor Necrosis Factor-alpha (analysis), Wuchereria bancrofti (immunology).
- MESH :
- chemical , administration & dosage : Diethylcarbamazine, Ivermectin.
- chemical , analysis : Tumor Necrosis Factor-alpha.
- chemical , blood : Antibodies, Helminth, Antigens, Helminth, Interleukins.
- chemical , immunology : Antigens, Helminth.
- chemical , therapeutic use : Diethylcarbamazine, Ivermectin.
- drug therapy : Elephantiasis, Filarial.
- immunology : Elephantiasis, Filarial, Microfilariae, Wuchereria bancrofti.
- Adolescent, Adult, Animals, Female, Humans, Hypersensitivity, Immediate, Male, Middle Aged.
Abstract
We compared the effect of a single dose of ivermectin with that of a standard course of diethylcarbamazine (DEC) on several parameters of the host's antifilarial immune response in 60 patients with bancroftian filariasis enrolled in a double-blind drug trial. All participants had measurable serum levels of antifilarial antibodies and parasite antigens at the onset of the study. Drug-induced clearance of microfilaremia was associated with a temporary increase in HC 11 antigenemia and a decrease in serum levels of antibodies to soluble filarial antigens. Antigenemia progressively declined in patients who remained amicrofilaremic after treatment, but declined and then increased in persons with recurrent microfilaremia. Treatment triggered a sustained increase in serum levels of interleukin-1, tumor necrosis factor, and interleukin-6 in all patients studied. Although ivermectin and DEC are believed to exert their antiparasite activity via different mechanisms, the same pattern of serologic changes was observed in patients treated with either drug.
PubMed: 1877712
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :005B07
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :005B07
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :005B07
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :002F34
Links to Exploration step
pubmed:1877712Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment.</title>
<author><name sortKey="Zheng, H J" sort="Zheng, H J" uniqKey="Zheng H" first="H J" last="Zheng">H J Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Guizhou Provincial Institute of Parasitic Diseases, Guiyang, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guizhou Provincial Institute of Parasitic Diseases, Guiyang</wicri:regionArea>
<wicri:noRegion>Guiyang</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tao, Z H" sort="Tao, Z H" uniqKey="Tao Z" first="Z H" last="Tao">Z H Tao</name>
</author>
<author><name sortKey="Cheng, W F" sort="Cheng, W F" uniqKey="Cheng W" first="W F" last="Cheng">W F Cheng</name>
</author>
<author><name sortKey="Wang, S H" sort="Wang, S H" uniqKey="Wang S" first="S H" last="Wang">S H Wang</name>
</author>
<author><name sortKey="Cheng, S H" sort="Cheng, S H" uniqKey="Cheng S" first="S H" last="Cheng">S H Cheng</name>
</author>
<author><name sortKey="Ye, Y M" sort="Ye, Y M" uniqKey="Ye Y" first="Y M" last="Ye">Y M Ye</name>
</author>
<author><name sortKey="Luo, L F" sort="Luo, L F" uniqKey="Luo L" first="L F" last="Luo">L F Luo</name>
</author>
<author><name sortKey="Chen, X R" sort="Chen, X R" uniqKey="Chen X" first="X R" last="Chen">X R Chen</name>
</author>
<author><name sortKey="Gan, G B" sort="Gan, G B" uniqKey="Gan G" first="G B" last="Gan">G B Gan</name>
</author>
<author><name sortKey="Piessens, W F" sort="Piessens, W F" uniqKey="Piessens W" first="W F" last="Piessens">W F Piessens</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="1991">1991</date>
<idno type="RBID">pubmed:1877712</idno>
<idno type="pmid">1877712</idno>
<idno type="wicri:Area/PubMed/Corpus">005B07</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">005B07</idno>
<idno type="wicri:Area/PubMed/Curation">005B07</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">005B07</idno>
<idno type="wicri:Area/PubMed/Checkpoint">005B07</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">005B07</idno>
<idno type="wicri:Area/Ncbi/Merge">002F34</idno>
<idno type="wicri:Area/Ncbi/Curation">002F34</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment.</title>
<author><name sortKey="Zheng, H J" sort="Zheng, H J" uniqKey="Zheng H" first="H J" last="Zheng">H J Zheng</name>
<affiliation wicri:level="1"><nlm:affiliation>Guizhou Provincial Institute of Parasitic Diseases, Guiyang, People's Republic of China.</nlm:affiliation>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Guizhou Provincial Institute of Parasitic Diseases, Guiyang</wicri:regionArea>
<wicri:noRegion>Guiyang</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Tao, Z H" sort="Tao, Z H" uniqKey="Tao Z" first="Z H" last="Tao">Z H Tao</name>
</author>
<author><name sortKey="Cheng, W F" sort="Cheng, W F" uniqKey="Cheng W" first="W F" last="Cheng">W F Cheng</name>
</author>
<author><name sortKey="Wang, S H" sort="Wang, S H" uniqKey="Wang S" first="S H" last="Wang">S H Wang</name>
</author>
<author><name sortKey="Cheng, S H" sort="Cheng, S H" uniqKey="Cheng S" first="S H" last="Cheng">S H Cheng</name>
</author>
<author><name sortKey="Ye, Y M" sort="Ye, Y M" uniqKey="Ye Y" first="Y M" last="Ye">Y M Ye</name>
</author>
<author><name sortKey="Luo, L F" sort="Luo, L F" uniqKey="Luo L" first="L F" last="Luo">L F Luo</name>
</author>
<author><name sortKey="Chen, X R" sort="Chen, X R" uniqKey="Chen X" first="X R" last="Chen">X R Chen</name>
</author>
<author><name sortKey="Gan, G B" sort="Gan, G B" uniqKey="Gan G" first="G B" last="Gan">G B Gan</name>
</author>
<author><name sortKey="Piessens, W F" sort="Piessens, W F" uniqKey="Piessens W" first="W F" last="Piessens">W F Piessens</name>
</author>
</analytic>
<series><title level="j">The American journal of tropical medicine and hygiene</title>
<idno type="ISSN">0002-9637</idno>
<imprint><date when="1991" type="published">1991</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Animals</term>
<term>Antibodies, Helminth (blood)</term>
<term>Antigens, Helminth (blood)</term>
<term>Antigens, Helminth (immunology)</term>
<term>Diethylcarbamazine (administration & dosage)</term>
<term>Diethylcarbamazine (therapeutic use)</term>
<term>Elephantiasis, Filarial (drug therapy)</term>
<term>Elephantiasis, Filarial (immunology)</term>
<term>Female</term>
<term>Humans</term>
<term>Hypersensitivity, Immediate</term>
<term>Interleukins (blood)</term>
<term>Ivermectin (administration & dosage)</term>
<term>Ivermectin (therapeutic use)</term>
<term>Male</term>
<term>Microfilariae (immunology)</term>
<term>Middle Aged</term>
<term>Tumor Necrosis Factor-alpha (analysis)</term>
<term>Wuchereria bancrofti (immunology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Anticorps antihelminthe (sang)</term>
<term>Antigènes d'helminthe (immunologie)</term>
<term>Antigènes d'helminthe (sang)</term>
<term>Diéthylcarbamazine (administration et posologie)</term>
<term>Diéthylcarbamazine (usage thérapeutique)</term>
<term>Facteur de nécrose tumorale alpha (analyse)</term>
<term>Femelle</term>
<term>Filariose lymphatique (immunologie)</term>
<term>Filariose lymphatique (traitement médicamenteux)</term>
<term>Humains</term>
<term>Hypersensibilité immédiate</term>
<term>Interleukines (sang)</term>
<term>Ivermectine (administration et posologie)</term>
<term>Ivermectine (usage thérapeutique)</term>
<term>Microfilaria (immunologie)</term>
<term>Mâle</term>
<term>Wuchereria bancrofti (immunologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Helminth</term>
<term>Antigens, Helminth</term>
<term>Interleukins</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Antigens, Helminth</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Diethylcarbamazine</term>
<term>Ivermectin</term>
</keywords>
<keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term>
</keywords>
<keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Antigènes d'helminthe</term>
<term>Filariose lymphatique</term>
<term>Microfilaria</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Elephantiasis, Filarial</term>
<term>Microfilariae</term>
<term>Wuchereria bancrofti</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antihelminthe</term>
<term>Antigènes d'helminthe</term>
<term>Interleukines</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Diéthylcarbamazine</term>
<term>Ivermectine</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Animals</term>
<term>Female</term>
<term>Humans</term>
<term>Hypersensitivity, Immediate</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term>
<term>Adulte</term>
<term>Adulte d'âge moyen</term>
<term>Animaux</term>
<term>Femelle</term>
<term>Humains</term>
<term>Hypersensibilité immédiate</term>
<term>Mâle</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">We compared the effect of a single dose of ivermectin with that of a standard course of diethylcarbamazine (DEC) on several parameters of the host's antifilarial immune response in 60 patients with bancroftian filariasis enrolled in a double-blind drug trial. All participants had measurable serum levels of antifilarial antibodies and parasite antigens at the onset of the study. Drug-induced clearance of microfilaremia was associated with a temporary increase in HC 11 antigenemia and a decrease in serum levels of antibodies to soluble filarial antigens. Antigenemia progressively declined in patients who remained amicrofilaremic after treatment, but declined and then increased in persons with recurrent microfilaremia. Treatment triggered a sustained increase in serum levels of interleukin-1, tumor necrosis factor, and interleukin-6 in all patients studied. Although ivermectin and DEC are believed to exert their antiparasite activity via different mechanisms, the same pattern of serologic changes was observed in patients treated with either drug.</div>
</front>
</TEI>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002F34 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 002F34 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Sante |area= LymphedemaV1 |flux= Ncbi |étape= Curation |type= RBID |clé= pubmed:1877712 |texte= Efficacy of ivermectin for control of microfilaremia recurring after treatment with diethylcarbamazine. II. Immunologic changes following treatment. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:1877712" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \ | NlmPubMed2Wicri -a LymphedemaV1
![]() | This area was generated with Dilib version V0.6.31. | ![]() |